Cyclic GMP-Dependent Signaling in Cardiac Myocytes

DOI Web Site PubMed 被引用文献5件 参考文献78件
  • Takimoto Eiki
    Division of Cardiology, Johns Hopkins University Division of Cardiology, Johns Hopkins University

この論文をさがす

抄録

Cyclic GMP (cGMP) and its effector kinase PKG regulate diverse cellular functions. In cardiac myocytes, cGMP is produced by soluble and particulate guanylyl cyclases (GCs), the former stimulated by nitric oxide and the latter by natriuretic peptides, and is hydrolyzed to inactive 5′-GMP by cGMP-phosphodiesterases (PDEs). cGMP-PKG modulates cardiac contractility, hypertrophy and remodeling, and exerts cardioprotection. Although early research efforts have mostly focused on cGMP synthetic pathways, recent studies have revealed that cGMP degradation controlled by PDEs plays a critical role in the physiological action of cGMP. Among several cGMP-PDEs, cGMP-specific PDE5 has been intensively investigated. Studies in experimental animal models and humans consistently demonstrate benefits from PDE5 inhibitors in various cardiac pathologies. Several clinical trials are ongoing or planned to test the efficacy of PDE5 inhibitors in human heart disease, including a large multicenter clinical trial (RELAX) led by the NIH evaluating sildenafil efficacy in heart failure with preserved ejection fraction. This review underscores the current understanding of cGMP-PKG signal regulation and its pathophysiological role in the heart, focusing on cardiac myocytes.  (Circ J 2012; 76: 1819–1825)<br>

収録刊行物

  • Circulation Journal

    Circulation Journal 76 (8), 1819-1825, 2012

    一般社団法人 日本循環器学会

被引用文献 (5)*注記

もっと見る

参考文献 (78)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ